Harmony Biosciences Holdings, Inc. (HRMY) Q4 FY25 Earnings Call

WAKIX momentum supports 2026 blockbuster guidance, but litigation and rising pipeline investment remain key execution risks.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-25
Length61 minutes
EPS$0.38
EPS consensus$0.84
Revenue$243.8M
Revenue consensus$240.3M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All HRMY earnings ยท Back to HRMY overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.